<DOC>
	<DOCNO>NCT02547454</DOCNO>
	<brief_summary>This observational trial examine efficacy safety Mircera renal anemia participant stage III-IV CKD daily clinical practice . Mircera prescribe treat physician follow approximately 36 month .</brief_summary>
	<brief_title>An Observational Study Evaluate Effectiveness Mircera Treatment Renal Anemia Pre-dialysis Participants With Chronic Kideny Disease ( CKD )</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>Participants age &gt; 18 year CKD Participants eligible Mircera treatment accord current guideline summary product characteristic ( SmPC ) Nonrenal anemia Pregnancy breastfeeding Uncontrolled hypertension Known hypersensitivity methoxy polyethylene glycolepoetin beta Administration study drug within 30 day prior study enrollment</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>